Min Park Appointed As Chief Commercial Officer At Matica Bio

Min Park has been appointed Chief Commercial Officer at Matica Biotechnology, overseeing commercial operations and spearheading initiatives to establish a long-term growth strategy for the company. Park brings over 25 years of extensive experience in global commercial operations within the life sciences sector. His track record includes launching multiple global Cell and Gene Therapy and Biologics CDMOs, often achieving ambitious targets.

Paul Kim, CEO of Matica Bio, said in a statement, “We are excited to welcome Min Park to Matica Bio’s executive team. He has a wealth of experience in leading commercial teams and commercial strategy with customer value generation in mind. We look forward to his leadership and are excited for the opportunity to leverage his industry knowledge, experience, and expertise to create next-generation customer-centric CDMO to advance additional clinical pipeline candidates to market.”

Before joining Matica Bio, Park held leadership positions at prominent organizations, including Aton Biotech (a Henlius Company), WuXi AppTec - WuXi Advanced Therapies, Abzena, Catalent, Samsung Biologics, and DSM. Alongside his industry roles, he serves as Chairman of the Board for the National Association of Asian American Professionals (NAAAP), the largest and fastest-growing 501(c)(3) organization in its field.  Park holds a Bachelor of Science from Montclair State University and an MBA in International Business from Louisiana State University. Fluent in English and Korean, he brings a global perspective and a wealth of expertise to his new role.  

Mr. Park, expressed, saying, “I’m excited to join Matica Bio’s team to create a customer-centric cell and gene therapy CDMO to support our partners to accelerate more life saving therapies from idea to patient. Our commitment to our clients' success and attitude to making it happen will generate endless value for our global partners.”